Testing cefiderocol and levofloxacin against hemorrhagic pneumonia

Hemorrhagic pneumonia in treatment groups
Compared to the control, LVFX and CFDC administered groups showed decreased lung damage.
  Image Credit: Osaka Metropolitan University

Scientific Frontline: Extended "At a Glance" Summary: Testing Antimicrobials Against Hemorrhagic Pneumonia

The Core Concept: A recent study evaluates the efficacy of two antimicrobial agents, cefiderocol (CFDC) and levofloxacin (LVFX), as treatments for severe hemorrhagic pneumonia caused by the multidrug-resistant bacterium Stenotrophomonas maltophilia.

Key Distinction/Mechanism: Both drugs improve survival rates and reduce bacterial burdens in the heart and lungs. LVFX provides more pronounced protection against lung hemorrhage because it more readily reaches pulmonary tissue; however, CFDC serves as a highly effective alternative when facing LVFX-resistant bacterial strains.

Major Frameworks/Components:

• Stenotrophomonas maltophilia: A multidrug-resistant pathogen that causes life-threatening infections in immunocompromised individuals.
• Levofloxacin (LVFX): A standard, highly effective antibiotic that is currently facing increasing rates of bacterial resistance.
• Cefiderocol (CFDC): A newer antimicrobial agent tested as a fallback therapeutic option.
• In vivo Murine Model: Utilized to measure overall survival rates, organ-specific bacterial burden, and microscopic hemorrhagic damage in lung tissue.

Branch of Science: Pharmacology, Infectious Diseases, Microbiology, Medicine.

Future Application: These findings will directly guide clinical decision-making, enabling medical professionals to select appropriate therapeutic agents based on specific antimicrobial resistance profiles and individual clinical scenarios.

Why It Matters: Because S. maltophilia infections are notoriously difficult to treat and frequently fatal, validating CFDC as a viable alternative treatment provides a critical defense against the escalating crisis of antibiotic resistance.

Drug resistance of Stenotrophomonas maltophilia prompts need for effective alternative treatments

Stenotrophomonas maltophilia (S. maltophilia) is a multidrug-resistant bacterium that can cause severe and life-threatening hemorrhagic pneumonia in individuals with weakened immune systems. Despite this, there are limited treatment options for this bacterium, and the infections it causes are extremely difficult to treat. The commonly used antibiotic levofloxacin (LVFX) currently stands as one of the most effective, but reported evidence of S. maltophilia resistance has been increasing. Alternatively, cefiderocol (CFDC), a new antimicrobial agent, has shown effectiveness against S. maltophilia in experimental studies. However, its efficacy against hemorrhagic pneumonia remains unclear.

Therefore, a research group led by Dr. Waki Imoto at Osaka Metropolitan University’s Graduate School of Medicine examined the effectiveness of CFDC and LVFX using a mouse model. After separating the mice into control, CFDC, and LVFX groups, the team administered the drugs to mice with severe hemorrhagic pneumonia caused by S. maltophilia and evaluated the effects of each treatment.

Consequently, both antimicrobial treatments improved survival rates and reduced bacterial burdens in the heart and lungs. In addition, a microscopic examination of lung tissue revealed reduced hemorrhage, indicating decreased lung damage. However, instances of hemorrhage differed between the LVFX and CFDC groups. In mice treated with LVFX, hemorrhage was rarely observed, whereas the CFDC group had slight occurrences.

“The effects observed in this study were more pronounced with LVFX. One possible reason is that it more readily reaches the lungs, which are the primary organs infected by the bacteria,” said Dr. Imoto. “On the other hand, because the emergence of LVFX-resistant strains has been reported, it is important to select appropriate therapeutic agents depending on the clinical situation while taking antimicrobial resistance into account and using CFDC as an alternative treatment for S. maltophilia.”

Additional information: The authors thank Shionogi & Co. Ltd. for providing CFDC and experimental advice.

Funding: This research was supported by the Japanese Society for Chemotherapy 70th Anniversary Research Support Program, JSPS KAKENHI (grant number 24K11659), Medical Research Grants from the Takeda Science Foundation (grant number 2024047731), and the Morinomiyako Medical Research Foundation (grant number 2021-01-02).

Published in journal: Antimicrobial Agents and Chemotherapy

Title: Efficacy of cefiderocol and levofloxacin against Stenotrophomonas maltophilia in a hemorrhagic pneumonia mouse model

Authors: Waki Imoto, Junko Abe, Norihiro Sakurai, Kengo Kawamoto, Koichi Yamada, Yukihiro Kaneko, and Hiroshi Kakeya

Source/Credit: Osaka Metropolitan University

Reference Number: phar051126_01

Privacy Policy | Terms of Service | Contact Us